This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

  • Clinicaltrials.gov identifier

    NCT03935074

  • Recruitment Status

    Completed

  • First Posted

    May 2, 2019

  • Last update posted

    May 6, 2019

Study Description

Brief summary:

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

  • Condition or Disease:Retinoblastoma
  • Intervention/Treatment: Drug: intra-arterial administration of melphalan
  • Phase: N/A

Detailed Description

N/A

Study Design

  • Study Type: Observational
  • Actual Enrollment: 30 participants
  • Observational Model: Case-Only
  • Time Perspective: Retrospective
  • Official Title: Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
  • Actual Study Start Date: August 2016
  • Actual Primary Completion Date: November 2016
  • Actual Study Completion Date: November 2016

Groups and Cohorts

Groups/Cohorts Intervention/treatment
: group 1
Patients who received intra-arterial chemotherapy as a first line treatment
Drug: intra-arterial administration of melphalan
: group 2
Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
Drug: intra-arterial administration of melphalan

Outcome Measures

  • Primary Outcome Measures: 1. globe salvage [ Time Frame: 2-5 years ]
    globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma

Eligibility Criteria

  • Ages Eligible for Study: 5 to 7 Months (Child)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers:
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients diagnosed with retinoblastoma and who received superselective intra-arterial chemotherapy as a first line treatment or as a salvage treatment after systemic chemotherapy

Criteria

Inclusion Criteria:

- patients diagnosed with unilateral/bilateral retinoblastoma

Exclusion Criteria:

- patients with trilateral retinoblastoma

- extraoculer involvement

- patients with blood dyscrasias, bleeding and clotting disorders

Contacts and Locations

Contacts

Locations

Turkey
Istanbul University Cerrahpasa School of Medicine Ophthalmology Department
Istanbul

Sponsors and Collaborators

Istanbul University-Cerrahpasa

More Information